Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Haemonetics (HAE) EBIT (2016 - 2025)

Historic EBIT for Haemonetics (HAE) over the last 17 years, with Q4 2025 value amounting to $67.4 million.

  • Haemonetics' EBIT rose 1417.44% to $67.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was $251.1 million, marking a year-over-year increase of 3916.81%. This contributed to the annual value of $221.8 million for FY2025, which is 3452.99% up from last year.
  • Haemonetics' EBIT amounted to $67.4 million in Q4 2025, which was up 1417.44% from $58.5 million recorded in Q3 2025.
  • In the past 5 years, Haemonetics' EBIT registered a high of $71.3 million during Q1 2025, and its lowest value of -$21.2 million during Q2 2021.
  • Over the past 5 years, Haemonetics' median EBIT value was $41.5 million (recorded in 2022), while the average stood at $39.1 million.
  • Its EBIT has fluctuated over the past 5 years, first plummeted by 18142.04% in 2021, then soared by 211345.32% in 2022.
  • Over the past 5 years, Haemonetics' EBIT (Quarter) stood at $24.5 million in 2021, then surged by 76.58% to $43.3 million in 2022, then grew by 6.24% to $46.0 million in 2023, then increased by 28.39% to $59.0 million in 2024, then increased by 14.17% to $67.4 million in 2025.
  • Its EBIT was $67.4 million in Q4 2025, compared to $58.5 million in Q3 2025 and $53.9 million in Q2 2025.